Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
Knee osteoarthritis, as a progressive disease is one of the most common causes of pain, motor disorder and disability in the elderly. By increasing age, the cartilage is eroded and endures degenerative changes due to physiological and biomechanical changes as well as metabolic effects and trauma . Non-surgical interventions for pain control of knee osteoarthritis include weight loss, exercise, changes in daily activities, physiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics .However ,the intra-articular injection is recently recommended by many studies such as corticosteroids, hyaluronic acid, Growth hormone, dextrose ,and platelet rich plasma. Intra-articular injection of platelets are activated and undergo degranulation, releasing a range of growth factors, including transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor, vascular endothelial growth factors, epidermal growth factors and basic fibroblast growth factor 2. These growth factors are thought to activate a variety of signaling pathways, which promote healing of bone and soft tissue.Also,some minimally invasive therapeutic options have been effective in pain relieve in KA, such as ultrasound-guided saphenous nerve block .

Detailed Description
-----------------
The aim of this study is to compare the efficacy of ultrasound guided saphenous nerve block versus platelet rich plasma injection in the management of chronic pain in patients with knee OA. This study will be conducted to evaluate which modality is more effective.

Official Title
-----------------
Ultra-sound Guided Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Joint Osteoarthritis

Conditions
-----------------
Chronic Knee Joint Osteoarthritis

Intervention / Treatment
-----------------
* Other: Saphenous nerve block group
* Other: Platelet rich plasma group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are not competent to understand the study protocol Radiographic evidence of OA of knee of 2nd degree. Chronic pain for at least 6 months prior to study entry (day 0). Pain relief not achieved with conservative therapies during the last 6 months Exclusion Criteria: Patient refusal. Bleeding disorders. Coagulation disorders. Local skin infection Current other problem in the affected extremity . Psychiatric disorders affecting co-operation of the patient . Previous chronic opioid use. Intra articular knee injection within previous three months. History of traumatic arthropathy. History of neuropathic arthropathy. Allergy or hypersensitivity to any of the study medication. Any condition that could interfere with the interpretation of the outcome assessments. Pregnancy Lactating women. low back pain due to central cause.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Saphenous nerve block group<br>Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg | Other: Saphenous nerve block group<br>* Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg<br>|
| Experimental: Platelet rich plasma group<br>Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma | Other: Platelet rich plasma group<br>* Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain scores | The severity of pain will be assessed using a visual analog scale (VAS) | For 6 months after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life (QOL) | is evaluated using the Western Ontario and MC Master universities (WOMAC) index of osteoarthritis | For 6 months after intervention |